Transfusion Indications and Component Therapy

A transfusion order is justified by a laboratory result in clinical context, an expected response from a specific component, and a plan for special processing or emergency support. The laboratory contributes the counts, coagulation results, compatibility record, and response measurements that confirm the component worked. Blood Product Processing, Storage, Components, and Quality Control covers component manufacture, storage conditions, labeling, and product quality control; this page follows the decision to transfuse through the choice of component and dose.

Expected response per component

Each component carries a predictable average effect in an average-sized adult, and the laboratory verifies that response with posttransfusion counts.¹

Pediatric doses are ordered by volume. CPD or CPDA-1 red cells at 5 to 15 mL/kg raise hemoglobin about 3 g/dL, additive-solution red cells at 10 to 15 mL/kg raise it about 2 g/dL, plasma at 10 to 15 mL/kg raises most factor levels about 15 to 20 percent, and cryoprecipitate at 1 to 2 units per 10 kg raises fibrinogen about 60 to 100 mg/dL under the assumed ideal recovery.¹

The per-unit red-cell increment depends on blood volume. A 90 kg adult with an estimated blood volume of 6,300 mL (90 kg × 70 mL/kg) and a hematocrit of 24% has a red-cell mass of 6,300 × 0.24 = 1,512 mL. One red-cell unit adds roughly 200 mL of red cells, giving 1,712 mL. After volume equilibration, the estimated hematocrit is 1,712 ÷ 6,300 = 27.2%, a rise of about 3.2 percentage points.²

Worked example. The same patient’s measured hematocrit the next morning is 26.8%. The observed rise is 2.8 percentage points against a predicted 3.2. The laboratory reports the posttransfusion value, and the care team interprets the difference against ongoing bleeding, hemodilution, and red-cell destruction before any further component order.

Platelet response is measured with the corrected count increment when repeated increments fall short of expectation. The formula, its 10-to-60-minute assessment window, and the interpretation of immune and nonimmune refractoriness are covered in the Leukocyte and Platelet Antigen Testing page. ABO-identical platelets give the best increments; group O recipients respond less well to group A platelets, and repeated ABO-incompatible platelet transfusion can produce a positive direct antiglobulin test from passively transferred anti-A or anti-B.²

Red cell thresholds

For most hospitalized, hemodynamically stable adults, current international guidance suggests a restrictive red-cell transfusion strategy with a threshold of 7 g/dL over a liberal one. Symptoms, comorbidity, the rate of hemoglobin decline, bleeding, and hemodynamic status determine whether a result below that value warrants transfusion.³

Hospitalized adults with acute myocardial infarction are a defined exception. A 2025 AABB international guideline suggests a liberal strategy for these patients when hemoglobin is below 10 g/dL, a conditional recommendation based on low-certainty evidence from trials showing fewer deaths under the liberal approach. The 7 g/dL general threshold should be applied to these patients only with the ischemic risk, bleeding status, and volume-overload risk in view.⁴

Red cells are indicated for symptomatic or critical deficit of oxygen-carrying capacity and for red-cell exchange. Anemia that specific hematinics such as iron, vitamin B₁₂, folate, or erythropoietin can correct is treated with those agents, and red-cell-containing components carry no indication for volume expansion or oncotic support alone.¹

Platelet support

Prophylactic platelet transfusion is appropriate for the clinically stable patient with an intact vascular system and normal platelet function at counts below 5,000 to 10,000/µL. Thrombocytopenia is unlikely to be the sole cause of bleeding at counts of 50,000/µL or above, and higher thresholds are appropriate for central nervous system bleeding and platelet-function defects.¹ Prophylactic transfusion is generally withheld in immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and heparin-induced thrombocytopenia unless life-threatening hemorrhage is present, because circulating antibodies destroy the transfused platelets along with the patient’s own.¹

Platelets carry ABO antigens on their surface and no Rh antigen, but residual red cells in the component expose a D-negative recipient to D. The alloimmunization risk is higher with whole-blood-derived platelets and very low with apheresis platelets. For a D-negative female of childbearing potential who receives D-positive platelets, Rh immune globulin is a candidate preventive measure, dosed from the estimated residual D-positive red-cell volume under the validated product and facility protocol.^1,5

Plasma and cryoprecipitate

Plasma replaces multiple coagulation factors at once. The current Circular of Information indicates plasma for preoperative or bleeding patients who need multiple factors, such as liver disease or disseminated intravascular coagulation; massive transfusion with clinically significant factor deficiency; urgent warfarin reversal when vitamin K cannot act in time; plasma exchange in thrombotic thrombocytopenic purpura; and factor deficiencies for which no concentrate is available.¹ Plasma must be ABO compatible with the recipient’s red cells, and D compatibility is unnecessary. A standard dose of about 15 mL/kg may leave a minimally elevated INR unchanged, and an INR of 1.7 or less reflects at least 30% factor activity, which supports normal hemostasis, so plasma is withheld from a minimally elevated INR in a nonbleeding patient.¹

Cryoprecipitate supplies fibrinogen, factor VIII, factor XIII, and von Willebrand factor in concentrated form. Factor concentrates are preferred for von Willebrand disease, hemophilia A, and factor XIII deficiency, so cryoprecipitate is reserved for fibrinogen deficiency, second-line use in those disorders, and selected uremic bleeding after other measures fail.¹

Worked example. A bleeding patient’s fibrinogen is 70 mg/dL and the target is 180 mg/dL, requiring an increase of 110 mg/dL. The estimated plasma volume is 2,800 mL, or 28 dL. Fibrinogen needed = 110 mg/dL × 28 dL = 3,080 mg. A standard 5-unit pool carries at least 750 mg (5 × 150 mg minimum per unit), so 3,080 ÷ 750 = 4.1, rounded up to 5 pools. Transfused fibrinogen recovery is 50% to 60%, so the measured fibrinogen response guides the next dose.¹

Plasma derivatives and factor concentrates

Plasma derivatives are manufactured from large plasma pools with product-specific viral inactivation, so their infection risk profile differs from that of single-donor components.

Factor VIII. Recombinant or virally inactivated plasma-derived factor VIII treats hemophilia A. One unit per kilogram raises the plasma factor VIII level about 2 percentage points, and the dose is calculated against plasma volume:

units = (target level − baseline level) × body weight (kg) × 70 mL/kg × (1 − hematocrit)

Worked example. A 70 kg patient with hematocrit 38% has a factor VIII level of 3% and a preprocedure target of 45%. Blood volume = 70 × 70 = 4,900 mL. Plasma volume = 4,900 × 0.62 = 3,038 mL. Units = 0.42 × 3,038 = about 1,276 units.

Factor IX. Recombinant factor IX or prothrombin complex concentrate treats hemophilia B. About half of an infused factor IX dose distributes outside the vascular space, so the calculated dose is doubled to reach the same target level.⁶

Other concentrates. Antithrombin and protein C concentrates treat their hereditary deficiencies. Protein S deficiency has no FDA-approved concentrate in the United States, and its management is clinical, with plasma reserved for selected severe situations.

Recombinant activated factor VII. rFVIIa treats bleeding in hemophilia A or B patients with inhibitors. Its use in severe liver disease and massive hemorrhage rests mainly on case series, with little evidence from large randomized trials.

Albumin. The 5% and 25% heat-treated solutions replace volume and are the standard apheresis replacement fluid. A 25% infusion draws about 3.5 times its own volume of fluid into the vascular space within minutes, with an osmotic effect roughly five times the infused volume, so adequate extravascular reserve is required before rapid infusion.⁷

Immune globulin. Intravenous or intramuscular immune globulin treats hypogammaglobulinemia, postexposure prophylaxis such as hepatitis A, and autoimmune disease through reticuloendothelial Fc-receptor blockade. Intramuscular immune globulin must never be given intravenously because of the risk of severe anaphylaxis.

Rh immune globulin. Anti-D immune globulin coats D-positive fetal or transfused red cells and clears them before maternal immunization. One 300 µg dose covers 15 mL of D-positive red cells or 30 mL of D-positive whole blood, and the calculated dose for a large exposure is rounded up to the next whole dose. The antenatal and postpartum dosing pathway, fetomaternal hemorrhage quantification, and passive-versus-immune anti-D interpretation are covered in the Hemolytic Disease of the Fetus and Newborn page.^5,8

Special processing requirements

Four modifications attach clinical indications to component selection. The processing and dating consequences of each modification are covered in the processing page.

Leukoreduction removes donor leukocytes to fewer than 5 × 10⁶ per unit for red cells, apheresis platelets, and pooled platelets, and fewer than 8.3 × 10⁵ for a single whole-blood-derived platelet. Prestorage filtration is preferred because bedside filtration lacks routine quality control and can cause severe hypotension in recipients taking angiotensin-converting enzyme inhibitors. Leukoreduced components reduce recurrent febrile nonhemolytic reactions, reduce HLA alloimmunization, and reduce cytomegalovirus transmission risk; their effects on hospital length of stay and postoperative infection remain unsettled.¹

Washing and freezing serve transfusion-specific indications. Washing removes residual plasma proteins and is indicated for recurrent severe allergic reactions and for IgA-deficient patients with anti-IgA, and washing removes the glycerol from thawed frozen red cells. Frozen storage preserves rare-phenotype units for as long as 10 years, and a deglycerolized unit expires 24 hours after thawing in an open system, with up to 14 days permitted in an approved closed system. The processing steps and quality-control specifications are covered in the processing page.^1,2

Cytomegalovirus risk reduction applies to seronegative recipients at risk of severe primary infection: pregnant women and their fetuses, low-birth-weight infants, hematopoietic progenitor cell and solid-organ transplant recipients, severely immunosuppressed recipients, and HIV-infected patients. CMV persists latently in mononuclear leukocytes, so prestorage leukoreduction or CMV-seronegative selection reduces transmission risk to comparable low levels; plasma and cryoprecipitate carry no meaningful CMV risk.¹

Irradiation prevents transfusion-associated graft-versus-host disease by rendering donor T lymphocytes incapable of proliferation. The standard dose is 2,500 cGy targeted to the central portion of the container with at least 1,500 cGy to every part of the component.¹ Three conditions must coexist for disease: viable donor T lymphocytes in the component, an HLA disparity in the direction the donor cells can attack, and a recipient unable to reject them. Irradiation is indicated for intrauterine transfusion recipients, selected neonatal and immunocompromised recipients, cellular components from blood relatives, hematopoietic progenitor cell transplant recipients, HLA-selected components, and granulocytes, which always carry the requirement. Purine analogue therapy and immunomodulators such as alemtuzumab or antithymocyte globulin create risk that depends on clinical factors, and Hodgkin lymphoma and purine analogue therapy are common additional indications. A crossmatch-compatible platelet unit carries an irradiation requirement when it is also HLA selected, when another indication applies, or when facility policy requires it. Universal irradiation requirements do not attach to solid-organ transplantation, acute leukemia, or low birth weight alone; the requirement follows the diagnosis, treatment regimen, timing, and facility policy, and the duration after transplant is program-specific.¹

Emergency and massive transfusion

Emergency release follows the facility procedure described in the Pretransfusion Testing page: the pretransfusion specimen is collected first whenever feasible, group O red cells or low-titer group O whole blood supports an unknown group under the medical-director-approved D-allocation policy, and ABO, D, and antibody testing continues in parallel. Low-titer cutoffs are facility-defined because no universal safe titer exists.^1,2

Massive transfusion means replacement of one blood volume within 24 hours, roughly 10 adult red cell units, or half a blood volume within 3 hours. Plasma and platelets are front-loaded before laboratory-documented coagulopathy develops, and subsequent component choice follows the laboratory.²

Large-volume transfusion carries metabolic consequences the laboratory can anticipate. Hypothermia from refrigerated blood worsens coagulopathy, and each 4 °C unit can lower core temperature by about 0.25 °C in an average adult. Citrate from the anticoagulant chelates ionized calcium; when delivery outpaces hepatic metabolism, perioral tingling, tetany, hyperventilation, and arrhythmia follow, with the greatest risk in liver failure and circulatory collapse, and ionized calcium measurement detects the change that total calcium misses. Potassium released during storage causes transient hyperkalemia that matters most in neonates and in renal, hepatic, or cardiac dysfunction. Dilutional coagulopathy develops as crystalloid and red-cell resuscitation proceeds without proportional plasma and platelets; platelet counts below 50,000/µL and factor levels near 25% are typical after roughly two blood-volume replacements.^1,2

Neonatal transfusion

Small-aliquot red-cell transfusion replaces phlebotomy losses and treats anemia of prematurity. Units less than 7 days old are preferred because they limit the hyperkalemia of storage and preserve 2,3-diphosphoglycerate, although some programs accept CPDA-1 red cells to 14 or 21 days under policy. CMV-risk reduction and irradiation follow the requirements above; irradiation is required for intrauterine transfusion and for subsequent neonatal transfusion after one. For exchange transfusion and for low birth weight alone, the irradiation and CMV requirements follow the current jurisdictional guideline and facility policy. Red cells for intrauterine, exchange, and other large-volume neonatal transfusions, and for known or suspected sickle cell disease, should be HbS negative, and urgent small-volume support proceeds under policy when such a unit is unavailable.^1,7

Oncology and chronically transfused patients

Repeated red-cell and platelet support progressively complicates compatibility. Red-cell alloimmunization complicates unit finding and raises delayed hemolytic reaction risk, and platelet refractoriness may require HLA-matched or crossmatch-compatible apheresis platelets as evaluated in the Leukocyte and Platelet Antigen Testing page. Chronic transfusion also accumulates iron at roughly 250 mg per unit, with significant accumulation possible after 10 to 20 transfusions, and serial ferritin follows the load.¹ Hematologic malignancies such as chronic lymphocytic leukemia and lymphoma are frequently associated with autoimmune hemolytic anemia, which complicates compatibility testing through the mechanisms described in the Warm, Mixed, and Drug-Induced Immune Hemolytic Anemia page.

Congenital and acquired coagulation deficiency support

Hemophilia A (factor VIII deficiency) is treated with recombinant or virally inactivated plasma-derived factor VIII concentrate; clinical disease generally appears below 10% activity, with spontaneous bleeding below 1%. Hemophilia B (factor IX deficiency) uses recombinant factor IX or prothrombin complex concentrate. von Willebrand disease is a quantitative or qualitative von Willebrand factor deficiency: type 1 is a partial quantitative deficiency, type 3 is near-absent von Willebrand factor, type 2A loses high-molecular-weight multimers, and type 2B is a gain-of-function multimer defect with increased platelet binding. Desmopressin releases endogenous von Willebrand factor and treats type 1 and some type 2A disease, with type 2B contraindicated because the released multimers worsen platelet aggregation.⁸

Vitamin K deficiency and warfarin effect. Vitamin K corrects the deficiency over hours, depending on route, and plasma is reserved for active bleeding or procedures that cannot wait for vitamin K to act.¹

Disseminated intravascular coagulation. Treatment targets the underlying cause, with plasma, platelets, or cryoprecipitate guided by serial PT, PTT, fibrinogen, and platelet results.

Platelet-function disorders. Drug effect, uremia, and congenital defects are managed by addressing the cause; dialysis clears the uremic toxins that coat and inactivate platelets, and desmopressin releases functional von Willebrand factor in uremic bleeding. Irreversible antiplatelet drugs such as clopidogrel are stopped about 5 to 7 days before elective surgery so platelet function returns.²

Surgical blood ordering

Most surgical procedures need no transfusion. A maximum surgical blood order schedule derived from the facility’s own procedure-specific transfusion experience, together with a type-and-screen policy, targets a crossmatch-to-transfusion ratio in the range of 2:1 to 3:1 and preserves inventory and testing time for patients with antibodies.²

References

1. Association for the Advancement of Blood & Biotherapies, American Red Cross, America's Blood Centers, Armed Services Blood Program. Circular of Information for the Use of Human Blood and Blood Components. June 2024. Accessed August 31, 2026.
2. Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026.
3. Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892-1902. doi:10.1001/jama.2023.12914.
4. Pagano MB, Stanworth SJ, Dennis J, et al. Red cell transfusion in acute myocardial infarction: AABB international clinical practice guidelines. Ann Intern Med. 2025;178(10):1469-1477. doi:10.7326/ANNALS-25-00706.
5. AABB. Association Bulletin #24-02: Use of Rh Immune Globulin and Considerations in the Setting of Supply Shortages and Limited Availability. July 15, 2024. Accessed August 31, 2026.
6. Kedrion Biopharma Inc. Buminate 25% [albumin human] prescribing information. DailyMed. Accessed August 31, 2026.
7. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-355. doi:10.1182/bloodadvances.2019001143.
8. Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325. doi:10.1182/bloodadvances.2020003264.